Retrospective evaluation of pubertal development and linear growth of girls with Turner Syndrome treated with oral and transdermal estrogen

J Pediatr Endocrinol Metab. 2015 Nov 1;28(11-12):1219-26. doi: 10.1515/jpem-2014-0007.

Abstract

Objective: The objective of the study was to evaluate the pubertal development and linear growth of Turner Syndrome (TS) girls regularly monitored in our department.

Patients and methods: The data of 13 patients with TS were evaluated retrospectively. Left hand radiograms were evaluated by three different pediatric endocrinologists to determine bone ages.

Results: Six (46.2%) of the TS girls were treated with oral estrogens, while 7 (53.8%) were treated with transdermal estrogen. The ratios of chronological age (CA) difference to bone age (BA) difference (ΔCA/ΔBA) in two groups of patients treated with estrogen were compared at the time of the last control. The ΔCA/ΔBA ratio in the transdermal estrogen-treated group was significantly higher (p=0.005). These results suggest slower BA progression in the TS girls treated with transdermal estrogen.

Conclusion: BA advancement is less significant with transdermal estrogen, which is associated with adequate breast development.

MeSH terms

  • Administration, Cutaneous
  • Administration, Oral
  • Adolescent
  • Body Height / drug effects*
  • Body Height / physiology
  • Child
  • Estradiol / administration & dosage
  • Estradiol / therapeutic use*
  • Estrogens / administration & dosage
  • Estrogens / therapeutic use*
  • Female
  • Humans
  • Puberty / drug effects*
  • Puberty / physiology
  • Retrospective Studies
  • Treatment Outcome
  • Turner Syndrome / drug therapy*
  • Turner Syndrome / physiopathology

Substances

  • Estrogens
  • Estradiol